AN2 Therapeutics Ownership | Who Owns AN2 Therapeutics?


OverviewForecastRevenueFinancialsChart

AN2 Therapeutics Ownership Summary


AN2 Therapeutics is owned by 65.23% institutional investors, 21.66% insiders, and 13.10% retail investors. Ra capital management is the largest institutional shareholder, holding 18.65% of ANTX shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 2.51% of its assets in AN2 Therapeutics shares.

ANTX Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockAN2 Therapeutics65.23%21.66%13.10%
SectorHealthcare Stocks 47.06%8.01%44.93%
IndustryBiotech Stocks 44.97%7.82%47.21%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Ra capital management5.55M18.65%$11.94M
Tcg crossover management1.56M5.22%$3.34M
Citadel advisors1.55M5.22%$3.34M
Vanguard group1.04M3.50%$2.24M
Millennium management526.35K1.77%$1.13M
Adage capital partners gp312.62K1.05%$672.12K
Blackrock299.70K1.01%$644.36K
Goldman sachs group224.19K0.75%$482.00K
Geode capital management180.92K0.61%$389.10K
Two sigma advisers, lp134.70K0.45%$289.61K

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Tcg crossover management1.56M0.35%$3.34M
Ra capital management5.55M0.16%$11.94M
Bridgeway capital management104.29K0.01%$224.23K
Adage capital partners gp312.62K0.00%$672.12K
Citadel advisors1.55M0.00%$3.34M
Acadian asset management86.95K0.00%$185.00K
Two sigma advisers, lp134.70K0.00%$289.61K
Two sigma investments, lp132.09K0.00%$283.99K
Millennium management526.35K0.00%$1.13M
Schonfeld strategic advisors21.77K0.00%$46.81K

Top Buyers

HolderShares% AssetsChange
Millennium management526.35K0.00%429.44K
Goldman sachs group224.19K0.00%195.81K
Two sigma advisers, lp134.70K0.00%134.70K
Bridgeway capital management104.29K0.01%78.00K
Two sigma investments, lp132.09K0.00%37.92K

Top Sellers

HolderShares% AssetsChange
Octagon capital advisors lp---3.22M
Frazier life sciences management---2.09M
Bvf inc/il---1.24M
Janus henderson group---1.22M
Avidity partners management lp---1.15M

New Positions

HolderShares% AssetsChangeValue
Two sigma advisers, lp134.70K0.00%134.70K$289.61K
Schonfeld strategic advisors21.77K0.00%21.77K$46.81K
Renaissance14.30K0.00%14.30K$30.75K
Royal bank of canada2.81K-2.81K$6.00K
Jpmorgan chase1.02K-1.02K$2.19K

Sold Out

HolderChange
Wells fargo & company/mn-128.00
California state teachers retirement system-9.25K
Clear street markets-10.00K
Qube research-10.19K
Atom investors lp-11.90K

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Jun 30, 202445-16.67%19,415,9093.64%651.04%20-35.48%13-18.75%
Mar 31, 2024545.88%18,733,564-8.13%791.26%31-3.13%1660.00%
Dec 31, 20235137.84%20,391,5032.31%790.76%3223.08%1025.00%
Sep 30, 20233719.35%19,931,49069.75%1022.79%26136.36%8-50.00%
Jun 30, 202331-16.22%11,741,51422.30%602.47%11-52.17%16128.57%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Vanguard Total Stock Mkt Idx Inv749.42K2.51%-
Vanguard Institutional Extnd Mkt Idx Tr261.93K0.88%-
Fidelity Extended Market Index121.94K0.41%23.68K
Bridgeway Ultra-Small Company Market101.79K0.34%78.00K
iShares Micro-Cap ETF35.46K0.12%-
BlackRock Extended Equity Market K33.77K0.11%-14.00
Fidelity Total Market Index31.36K0.11%-
Fidelity Series Total Market Index28.46K0.10%6.07K
Fidelity Nasdaq Composite Index17.97K0.06%-
Vanguard Instl Ttl Stck Mkt Idx Tr17.26K0.06%5.32K

Recent Insider Transactions


DateNameRoleActivityValue
Nov 18, 2024Easom Eric Chief Executive OfficerBuy$49.97K
Aug 14, 2024Leonard Braden Michael-Buy$1.56M
Aug 09, 2024RA CAPITAL MANAGEMENT, L.P.-Sell$123.94K
Aug 09, 2024RA CAPITAL MANAGEMENT, L.P.-Sell$3.68M
Jan 18, 2024Zakrzewski Joseph S-Sell$1.91M

Insider Transactions Trends


DateBuySell
2024 Q41-
2024 Q312
2024 Q2--
2024 Q1-12
2023 Q4-8

ANTX Ownership FAQ


Who Owns AN2 Therapeutics?

AN2 Therapeutics shareholders are primarily institutional investors at 65.23%, followed by 21.66% insiders and 13.11% retail investors. The average institutional ownership in AN2 Therapeutics's industry, Biotech Stocks , is 44.97%, which AN2 Therapeutics exceeds.

Who owns the most shares of AN2 Therapeutics?

AN2 Therapeutics’s largest shareholders are Ra capital management (5.55M shares, 18.65%), Tcg crossover management (1.56M shares, 5.22%), and Citadel advisors (1.55M shares, 5.22%). Together, they hold 29.10% of AN2 Therapeutics’s total shares outstanding.

Does Blackrock own AN2 Therapeutics?

Yes, BlackRock owns 1.01% of AN2 Therapeutics, totaling 299.7K shares as of Jun 2024. This represents 0% of BlackRock's total assets, with a market value of 644.36K$. In the last quarter, BlackRock increased its holdings by 8.62K shares, a 2.96% change.

Who is AN2 Therapeutics’s biggest shareholder by percentage of total assets invested?

Tcg crossover management is AN2 Therapeutics’s biggest shareholder by percentage of total assets invested, with 0.35% of its assets in 1.56M AN2 Therapeutics shares, valued at 3.34M$.

Who is the top mutual fund holder of AN2 Therapeutics shares?

Vanguard Total Stock Mkt Idx Inv is the top mutual fund holder of AN2 Therapeutics shares, with 2.51% of its total shares outstanding invested in 749.42K AN2 Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools